Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic,...
Hence then, the article about cellenkos inc announces fda clearance to initiate phase 2 clinical trial of ck0801 allogeneic cord blood derived tregs for aplastic anemia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia )
Also on site :
- Today’s Wordle Hint, Answers for 1773 on Monday, April 27, 2026
- Oil prices rise higher amid stalled US-Iran peace talks
- 37 Years Ago Today, Academy Award-Winning ’60s Actress, Died at 77